rob-wilson-shutterstock-com-1
Rob Wilson / Shutterstock.com
23 December 2016Asia-Pacific

Australia should change patent extension approach, says report

A report released by the Australian government has said Australia's extension of term (EoT) scheme for patents in the pharmaceutical industry "has had little effect" on investment and innovation.  An EoT grants pharmaceutical patents an additional five years of protection, after the initial 20 years.  According to the report, released by the Productivity Commission on Tuesday, December 20, the scheme's arrangements have "proven largely illusory".  More than half of new chemical entities approved in Australia have been awarded an extension, and consumers and governments therefore face higher prices for medicines in the extended years.  The report stated: "Rather than compensating firms for being slow to introduce drugs to the Australian market, extensions should only be allowed where the actions of the regulator result in an unreasonable delay." It added: "Timeframes (of around one year) set by government for the Therapeutic Goods Administration provide a ready benchmark for determining what constitutes a reasonable processing period. EoT should only be granted where the time taken by the regulator exceeds this period." With the new approach, the government estimates that it would lower the cost of drugs in Australia and save consumers, as well as taxpayers, more than A$250 million ($180 million) per year.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
22 April 2021   In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.

More on this story

Americas
22 April 2021   In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.

More on this story

Americas
22 April 2021   In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.